Drug intelligence / Profile preview

Scallop

Development stage: Unknown
Modality: Small Molecules
Administration: Intradermal, Subcutaneous, Sublingual

Overview

The term "Scallop" in a medical and scientific context is non-specific, referring to various applications and derivatives from the marine bivalve mollusk. While not a specific pharmaceutical drug itself, substances derived from scallops are under investigation for therapeutic purposes. The most prominent drug-like entity identified is scallop-derived plasmalogen, which has been studied for its potential effects on brain fatigue, body weight, and changes in blood plasmalogen levels in obese subjects. Other uses of the term "scallop" in the provided context include describing design features in medical devices (e.g., stent-grafts, orthodontic retainers) and as part of medical procedure names (e.g., BASILICA).

Other names: scallop-derived plasmalogen

Beyond the preview

Go deeper on Scallop.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scallop.

Explore the full profile